{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T21:20:41Z","timestamp":1773177641344,"version":"3.50.1"},"reference-count":130,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fundo Europeu de Desenvolvimento Regional (FEDER) funds through the COMPETE 2020 Operational Programme for Competitiveness and Internationalization (POCI)","award":["Portugal 2020"],"award-info":[{"award-number":["Portugal 2020"]}]},{"name":"Fundo Europeu de Desenvolvimento Regional (FEDER) funds through the COMPETE 2020 Operational Programme for Competitiveness and Internationalization (POCI)","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]},{"name":"Portuguese funds through Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia (FCT) in the framework of projects","award":["Portugal 2020"],"award-info":[{"award-number":["Portugal 2020"]}]},{"name":"Portuguese funds through Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia (FCT) in the framework of projects","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]},{"name":"Faculty of Medicine, University of Porto (FMUP)","award":["Portugal 2020"],"award-info":[{"award-number":["Portugal 2020"]}]},{"name":"Faculty of Medicine, University of Porto (FMUP)","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Pharmacology"],"abstract":"<jats:p>Pancreatic cancer constitutes a significant cause of cancer-related fatalities, with a five-year survival rate of only 12%. The most prevalent form of this disease is pancreatic ductal adenocarcinoma (PDAC). Given that a single therapeutic intervention has proven inadequate for the treatment of PDAC, it is essential to identify distinct molecular signatures that could improve treatment efficacy and alleviate the economic burden on patients. Surgery is recognized as the most effective treatment option for PDAC; however, only a small percentage of patients are candidates for this procedure due to the advanced stage of the disease at the time of diagnosis. In this context, we propose to explore the biology of PDAC with a focus on microbiome, epigenetics, and genetics. Our objective is to examine the existing knowledge in these areas and to identify potential pathways for personalized medicine. This approach holds promise for advancing our understanding of PDAC development, progression, and resistance to standard therapy.<\/jats:p>","DOI":"10.3390\/futurepharmacol4040049","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T07:42:18Z","timestamp":1734680538000},"page":"934-954","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Use of Personalized Medicine in Pancreatic Ductal Adenocarcinoma (PDAC): New Therapeutic Opportunities"],"prefix":"10.3390","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3028-8143","authenticated-orcid":false,"given":"In\u00eas","family":"Mendes","sequence":"first","affiliation":[{"name":"PerMed Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"School of Life and Environmental Sciences, University of Tr\u00e1s-os-Montes and Alto Douro (UTAD), Edif\u00edcio de Geoci\u00eancias, 5000-801 Vila Real, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-1042","authenticated-orcid":false,"given":"Nuno","family":"Vale","sequence":"additional","affiliation":[{"name":"PerMed Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Department of Community Medicine, Information and Health Decision Sciences (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer Statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1053\/j.gastro.2023.02.032","article-title":"Surveillance for Pancreatic Cancer in High-Risk Individuals Leads to Improved Outcomes: A Propensity Score-Matched Analysis","volume":"164","author":"Klatte","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/bs.pmbts.2016.09.008","article-title":"Molecular Pathogenesis of Pancreatic Cancer","volume":"144","author":"Grant","year":"2016","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Kommalapati, A., Tella, S.H., Goyal, G., Ma, W.W., and Mahipal, A. (2018). Contemporary Management of Localized Resectable Pancreatic Cancer. Cancers, 10.","DOI":"10.3390\/cancers10010024"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1053\/j.gastro.2022.03.056","article-title":"Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment","volume":"163","author":"Wood","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1038\/s41591-024-03239-5","article-title":"A framework for sharing of clinical and genetic data for precision medicine applications","volume":"30","author":"Elhussein","year":"2024","journal-title":"Nat. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1038\/s12276-024-01288-x","article-title":"Clinical application of whole-genome sequencing of solid tumors for precision oncology","volume":"56","author":"Kim","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0140-6736(14)61396-9","article-title":"40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971\u20132011: A population-based study","volume":"385","author":"Quaresma","year":"2015","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(19)30456-5","article-title":"Progress in cancer survival, mortality, and incidence in seven high-income countries 1995\u20132014 (ICBP SURVMARK-2): A population-based study","volume":"20","author":"Arnold","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.soc.2021.06.008","article-title":"Precision Medicine and Pancreatic Cancer","volume":"30","author":"George","year":"2021","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"215834","DOI":"10.1016\/j.canlet.2022.215834","article-title":"Single cell RNA-seq reveals the CCL5\/SDC1 receptor-ligand interaction between T cells and tumor cells in pancreatic cancer","volume":"545","author":"Chen","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"216636","DOI":"10.1016\/j.canlet.2024.216636","article-title":"Precision treatment of pancreatic ductal adenocarcinoma","volume":"585","author":"Wei","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41575-018-0005-x","article-title":"Therapeutic developments in pancreatic cancer: Current and future perspectives","volume":"15","author":"Neoptolemos","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pan.2018.10.003","article-title":"Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe","volume":"19","author":"Javed","year":"2019","journal-title":"Pancreatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.surge.2010.03.001","article-title":"Clinical presentation and waiting time targets do not affect prognosis in patients with pancreatic cancer","volume":"8","author":"Raptis","year":"2010","journal-title":"Surgeon"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1158\/2159-8290.CD-11-0347","article-title":"A central role for RAF\u2192MEK\u2192ERK signaling in the genesis of pancreatic ductal adenocarcinoma","volume":"2","author":"Collisson","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3892\/mco.2015.716","article-title":"Meta-analyses of treatment standards for pancreatic cancer","volume":"4","author":"Gong","year":"2016","journal-title":"Mol. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2017.03.025","article-title":"Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?","volume":"115","author":"Aprile","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Binda, C., Gibiino, G., Sbrancia, M., Coluccio, C., Cazzato, M., Carloni, L., Cucchetti, A., Ercolani, G., Sambri, V., and Fabbri, C. (2022). Microbiota in the Natural History of Pancreatic Cancer: From Predisposition to Therapy. Cancers, 15.","DOI":"10.3390\/cancers15010001"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3892\/ijo.2021.5281","article-title":"Role of the microbiome in systemic therapy for pancreatic ductal adenocarcinoma (Review)","volume":"59","author":"Huang","year":"2021","journal-title":"Int. J. Oncol."},{"key":"ref_25","first-page":"119","article-title":"Studies in 2-acetylaminofluorene carcinogenesis. III. The utilization of uracil-2-C14 by preneoplastic rat liver and rat hepatoma","volume":"14","author":"Rutman","year":"1954","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Sethy, C., and Kundu, C.N. (2021). 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition. Biomed. Pharmacother., 137.","DOI":"10.1016\/j.biopha.2021.111285"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: Mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"23713","DOI":"10.18632\/oncotarget.15785","article-title":"dUTPase inhibition augments replication defects of 5-Fluorouracil","volume":"8","author":"Hagenkort","year":"2017","journal-title":"Oncotarget"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"107447","DOI":"10.1016\/j.pharmthera.2019.107447","article-title":"5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future","volume":"206","author":"Vodenkova","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1200\/JCO.19.00946","article-title":"Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update","volume":"37","author":"Khorana","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1200\/JCO.1988.6.10.1653","article-title":"Fluorouracil: Biochemistry and pharmacology","volume":"6","author":"Pinedo","year":"1988","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.3332\/ecancer.2022.1344","article-title":"Dihydropyrimidine dehydrogenase (DPD) polymorphisms knocking on the door","volume":"16","author":"Donadio","year":"2022","journal-title":"Ecancermedicalscience"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Forouzesh, D.C., and Moran, G.R. (2021). Mammalian dihydropyrimidine dehydrogenase. Arch. Biochem. Biophys., 714.","DOI":"10.1016\/j.abb.2021.109066"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic Cancer: A Review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/JP9.0000000000000052","article-title":"The Achilles\u2019 Heel of Pancreatic Cancer: Targeting pancreatic cancer\u2019s unique immunologic characteristics and metabolic dependencies in clinical trials","volume":"3","author":"Siolas","year":"2020","journal-title":"J. Pancreatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/1758834012453755","article-title":"Harnessing gemcitabine metabolism: A step towards personalized medicine for pancreatic cancer","volume":"4","author":"Saif","year":"2012","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.297.3.267","article-title":"Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial","volume":"297","author":"Oettle","year":"2007","journal-title":"JAMA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"216640","DOI":"10.1016\/j.canlet.2024.216640","article-title":"CSNK2A1 confers gemcitabine resistance to pancreatic ductal adenocarcinoma via inducing autophagy","volume":"585","author":"Liu","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"D668","DOI":"10.1093\/nar\/gkj067","article-title":"DrugBank: A comprehensive resource for in silico drug discovery and exploration","volume":"34","author":"Wishart","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Mendes, I., and Vale, N. (2024). Overcoming Microbiome-Acquired Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Biomedicines, 12.","DOI":"10.3390\/biomedicines12010227"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1097\/PAS.0000000000000533","article-title":"A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas","volume":"39","author":"Basturk","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.gassur.2006.08.018","article-title":"1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience","volume":"10","author":"Winter","year":"2006","journal-title":"J. Gastrointest. Surg."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1136\/gutjnl-2017-315062","article-title":"IPMNs with co-occurring invasive cancers: Neighbours but not always relatives","volume":"67","author":"Felsenstein","year":"2018","journal-title":"Gut"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00000478-199904000-00005","article-title":"Mucinous cystic tumors of the pancreas: Clinicopathological features, prognosis, and relationship to other mucinous cystic tumors","volume":"23","author":"Zamboni","year":"1999","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"802","DOI":"10.2214\/AJR.07.3340","article-title":"Prevalence of unsuspected pancreatic cysts on MDCT","volume":"191","author":"Laffan","year":"2008","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jcmgh.2021.07.014","article-title":"Uncertain Beginnings: Acinar and Ductal Cell Plasticity in the Development of Pancreatic Cancer","volume":"13","author":"Grimont","year":"2022","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/0092-8674(88)90571-5","article-title":"Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes","volume":"53","author":"Almoguera","year":"1988","journal-title":"Cell"},{"key":"ref_49","first-page":"1534","article-title":"Pancreatic adenocarcinomas frequently show p53 gene mutations","volume":"142","author":"Scarpa","year":"1993","journal-title":"Am. J. Pathol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ng0994-27","article-title":"Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma","volume":"8","author":"Caldas","year":"1994","journal-title":"Nat. Genet."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1126\/science.271.5247.350","article-title":"DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1","volume":"271","author":"Hahn","year":"1996","journal-title":"Science"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1126\/science.1164368","article-title":"Core signaling pathways in human pancreatic cancers revealed by global genomic analyses","volume":"321","author":"Jones","year":"2008","journal-title":"Science"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature11547","article-title":"Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes","volume":"491","author":"Biankin","year":"2012","journal-title":"Nature"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"key":"ref_56","unstructured":"Cancer Genome Atlas Research Network (2017). Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell, 32, 185\u2013203.e13."},{"key":"ref_57","unstructured":"ICGC\/TCGA Pan-Cancer Analysis of Whole Genomes Consortium (2020). Pan-cancer analysis of whole genomes. Nature, 578, 82\u201393."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nature19823","article-title":"A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns","volume":"538","author":"Notta","year":"2016","journal-title":"Nature"},{"key":"ref_59","first-page":"3126","article-title":"Abrogation of the Rb\/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas","volume":"57","author":"Schutte","year":"1997","journal-title":"Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1158\/1078-0432.CCR-10-3431","article-title":"Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma","volume":"17","author":"Vincent","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/ng.3753","article-title":"Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis","volume":"49","author":"McDonald","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/S0002-9440(10)61104-2","article-title":"Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma","volume":"160","author":"Fukushima","year":"2002","journal-title":"Am. J. Pathol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/modpathol.3800991","article-title":"CpG island methylation profile of pancreatic intraepithelial neoplasia","volume":"21","author":"Sato","year":"2008","journal-title":"Mod. Pathol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/gast.2002.34160","article-title":"Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas","volume":"123","author":"Sato","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/path.5682","article-title":"Downregulation of 5-hydroxymethylcytosine is an early event in pancreatic tumorigenesis","volume":"254","author":"Fujikura","year":"2021","journal-title":"J. Pathol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.cgh.2018.08.045","article-title":"The Gut Microbiome in Pancreatic Disease","volume":"17","author":"Akshintala","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Herremans, K.M., Riner, A.N., Cameron, M.E., McKinley, K.L., Triplett, E.W., Hughes, S.J., and Trevino, J.G. (2022). The oral microbiome, pancreatic cancer and human diversity in the age of precision medicine. Microbiome, 10.","DOI":"10.1186\/s40168-022-01262-7"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ccell.2019.11.004","article-title":"The Tumor Microbiome in Pancreatic Cancer: Bacteria and Beyond","volume":"36","author":"McAllister","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41419-021-04293-4","article-title":"Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4\/MyD88\/AKT\/NF-\u03baB pathway in pancreatic cancer","volume":"12","author":"Yin","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_70","first-page":"77","article-title":"Identification of biliary bile acids in patients with benign biliary diseases, hepatocellular carcinoma and cholangiocarcinoma","volume":"13","author":"Jusakul","year":"2012","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00008469-199303000-00008","article-title":"Biliary bile acids in cholelithiasis and carcinoma of the gall bladder","volume":"2","author":"Shukla","year":"1993","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1756-8722-4-41","article-title":"Impact of bile acids on the growth of human cholangiocarcinoma via FXR","volume":"4","author":"Dai","year":"2011","journal-title":"J. Hematol. Oncol."},{"key":"ref_73","first-page":"2637","article-title":"Expressions of farnesoid X receptor and myeloid cell leukemia sequence 1 protein are associated with poor prognosis in patients with gallbladder cancer","volume":"127","author":"Wang","year":"2014","journal-title":"Chin. Med. J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"G1245","DOI":"10.1152\/ajpgi.00439.2011","article-title":"Downregulation of nuclear receptor FXR is associated with multiple malignant clinicopathological characteristics in human hepatocellular carcinoma","volume":"303","author":"Su","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/MCO.0000000000000584","article-title":"Microbiota and nonalcoholic fatty liver disease: Promising prospects for clinical interventions?","volume":"22","author":"Knudsen","year":"2019","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Badawy, A.A. (2022). Tryptophan metabolism and disposition in cancer biology and immunotherapy. Biosci. Rep., 42.","DOI":"10.1042\/BSR20221682"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Alvandi, E., Wong, W.K.M., Joglekar, M.V., Spring, K.J., and Hardikar, A.A. (2022). Short-chain fatty acid concentrations in the incidence and risk-stratification of colorectal cancer: A systematic review and meta-analysis. BMC Med., 20.","DOI":"10.1186\/s12916-022-02529-4"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/gepi.21758","article-title":"Mendelian randomization analysis with multiple genetic variants using summarized data","volume":"37","author":"Burgess","year":"2013","journal-title":"Genet. Epidemiol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Daniel, N., Farinella, R., Chatziioannou, A.C., Jenab, M., May\u00e9n, A.L., Rizzato, C., Belluomini, F., Canzian, F., Tavanti, A., and Keski-Rahkonen, P. (2024). Genetically predicted gut bacteria, circulating bacteria-associated metabolites and pancreatic ductal adenocarcinoma: A Mendelian randomisation study. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-77431-5"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ijc.29025","article-title":"Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity","volume":"136","author":"Froehlich","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","article-title":"Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: A systematic review and meta-analysis of individual patient data","volume":"16","author":"Meulendijks","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.2217\/pgs.15.70","article-title":"Translating DPYD genotype into DPD phenotype: Using the DPYD gene activity score","volume":"16","author":"Henricks","year":"2015","journal-title":"Pharmacogenomics"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","article-title":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: A prospective safety analysis","volume":"19","author":"Henricks","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/cncr.11040","article-title":"Cancer chronotherapy: Principles, applications, and perspectives","volume":"97","author":"Mormont","year":"2003","journal-title":"Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/bcp.13007","article-title":"Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers","volume":"82","author":"Jacobs","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s00432-001-0309-y","article-title":"Circadian variation of dihydropyrimidine dehydrogenase mRNA expression in leukocytes and serum cortisol levels in patients with advanced gastrointestinal carcinomas compared to healthy controls","volume":"128","author":"Raida","year":"2002","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/sj.bjp.0705651","article-title":"Circadian rhythm of dihydrouracil\/uracil ratios in biological fluids: A potential biomarker for dihydropyrimidine dehydrogenase levels","volume":"141","author":"Jiang","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"ref_89","first-page":"197","article-title":"Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion","volume":"50","author":"Harris","year":"1990","journal-title":"Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/clpt.1994.123","article-title":"Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: Relationship with mucosal toxicity in patients with cancer","volume":"56","author":"Metzger","year":"1994","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_91","first-page":"1264","article-title":"Chronomodulation of chemotherapy against metastatic colorectal cancer. International Organization for Cancer Chronotherapy","volume":"31A","author":"Giacchetti","year":"1995","journal-title":"Eur. J. Cancer"},{"key":"ref_92","first-page":"1676","article-title":"Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients","volume":"48","author":"Petit","year":"1988","journal-title":"Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1146\/annurev.pharmtox.48.113006.094626","article-title":"Circadian timing in cancer treatments","volume":"50","author":"Okyar","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/07420520500179969","article-title":"Circadian rhythm in dihydropyrimidine dehydrogenase activity and reduced glutathione content in peripheral blood of nasopharyngeal carcinoma patients","volume":"22","author":"Zeng","year":"2005","journal-title":"Chronobiol. Int."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Hill, R.J.W., Innominato, P.F., L\u00e9vi, F., and Ballesta, A. (2020). Optimizing circadian drug infusion schedules towards personalized cancer chronotherapy. PLoS Comput. Biol., 16.","DOI":"10.1371\/journal.pcbi.1007218"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40262-016-0431-2","article-title":"Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study","volume":"56","author":"Paintaud","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/s41419-024-07138-y","article-title":"cNEK6 induces gemcitabine resistance by promoting glycolysis in pancreatic ductal adenocarcinoma via the SNRPA\/PPA2c\/mTORC1 axis","volume":"15","author":"Li","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13045-019-0776-8","article-title":"CircRNAs in cancer metabolism: A review","volume":"12","author":"Yu","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ccell.2017.06.004","article-title":"MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer","volume":"32","author":"Shukla","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Ghanbari Movahed, Z., Rastegari-Pouyani, M., Mohammadi, M.H., and Mansouri, K. (2019). Cancer cells change their glucose metabolism to overcome increased ROS: One step from cancer cell to cancer stem cell?. Biomed. Pharmacother., 112.","DOI":"10.1016\/j.biopha.2019.108690"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Nakao, K., Minato, N., and Uemoto, S. (2015). Innovative Medicine: Basic Research and Development [Internet], Springer.","DOI":"10.1007\/978-4-431-55651-0"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.chom.2019.06.011","article-title":"Precision Medicine Goes Microscopic: Engineering the Microbiome to Improve Drug Outcomes","volume":"26","author":"Lam","year":"2019","journal-title":"Cell Host Microbe"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nrd3975","article-title":"Platforms for antibiotic discovery","volume":"12","author":"Lewis","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1107\/S1744309110029088","article-title":"Viewing the human microbiome through three-dimensional glasses: Integrating structural and functional studies to better define the properties of myriad carbohydrate-active enzymes","volume":"66","author":"Turnbaugh","year":"2010","journal-title":"Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrmicro.2016.17","article-title":"The microbial pharmacists within us: A metagenomic view of xenobiotic metabolism","volume":"14","author":"Spanogiannopoulos","year":"2016","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1126\/science.aai9383","article-title":"Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women","volume":"356","author":"Klatt","year":"2017","journal-title":"Science"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1126\/science.aah5043","article-title":"Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine","volume":"357","author":"Geller","year":"2017","journal-title":"Science"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1073\/pnas.1000087107","article-title":"Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation","volume":"108","author":"Dethlefsen","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.addr.2016.04.032","article-title":"Microbiome therapeutics\u2014Advances and challenges","volume":"105","author":"Mimee","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cbpa.2013.04.011","article-title":"The human microbiome is a source of therapeutic drug targets","volume":"17","author":"Wallace","year":"2013","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e01304","DOI":"10.1128\/mBio.01304-16","article-title":"Molecular Basis for Lytic Bacteriophage Resistance in Enterococci","volume":"7","author":"Duerkop","year":"2016","journal-title":"mBio"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nbt.4222","article-title":"Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria","volume":"36","author":"Isabella","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41592-018-0301-y","article-title":"Metagenomic engineering of the mammalian gut microbiome in situ","volume":"16","author":"Ronda","year":"2019","journal-title":"Nat. Methods"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Chen, S.M., Chieng, W.W., Huang, S.W., Hsu, L.J., and Jan, M.S. (2020). The synergistic tumor growth-inhibitory effect of probiotic Lactobacillus on transgenic mouse model of pancreatic cancer treated with gemcitabine. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-77322-5"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/jgm.2698","article-title":"Gene therapy clinical trials worldwide to 2012\u2014An update","volume":"15","author":"Ginn","year":"2013","journal-title":"J. Gene Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(13)70173-6","article-title":"Is cancer gene therapy an empty suit?","volume":"14","author":"Brenner","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1517\/14712598.2015.1001734","article-title":"Gene and cell therapy for pancreatic cancer","volume":"15","author":"Singh","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_119","first-page":"555","article-title":"A phase I\/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma","volume":"9","author":"Hecht","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.gie.2011.10.007","article-title":"EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: A phase I\/II study","volume":"75","author":"Hecht","year":"2012","journal-title":"Gastrointest. Endosc."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1200\/JCO.2012.44.7516","article-title":"Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: Final results","volume":"31","author":"Herman","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/cgt.2010.65","article-title":"A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer","volume":"18","author":"Nakao","year":"2011","journal-title":"Cancer Gene Ther."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/mt.2016.66","article-title":"Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma","volume":"24","author":"Noonan","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1089\/104303403321070810","article-title":"Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors","volume":"14","author":"Wang","year":"2003","journal-title":"Hum. Gene Ther."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.ymthe.2005.03.017","article-title":"Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma","volume":"12","author":"Tai","year":"2005","journal-title":"Mol. Ther."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/mt.2012.83","article-title":"Design and selection of Toca 511 for clinical use: Modified retroviral replicating vector with improved stability and gene expression","volume":"20","author":"Perez","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"341ra75","DOI":"10.1126\/scitranslmed.aad9784","article-title":"Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma","volume":"8","author":"Cloughesy","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41417-018-0020-7","article-title":"Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer","volume":"25","author":"Inoko","year":"2018","journal-title":"Cancer Gene Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"200769","DOI":"10.1016\/j.omton.2024.200769","article-title":"Development of gemcitabine-modified miRNA mimics as cancer therapeutics for pancreatic ductal adenocarcinoma","volume":"32","author":"Yuen","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/s41392-024-01973-3","article-title":"Aptamer-drug conjugates-loaded bacteria for pancreatic cancer synergistic therapy","volume":"9","author":"Xiao","year":"2024","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Future Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2673-9879\/4\/4\/49\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:56:01Z","timestamp":1760115361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2673-9879\/4\/4\/49"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":130,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["futurepharmacol4040049"],"URL":"https:\/\/doi.org\/10.3390\/futurepharmacol4040049","relation":{},"ISSN":["2673-9879"],"issn-type":[{"value":"2673-9879","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]}}}